Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma
Related Experiment Video
Updated: Apr 15, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Yasuhiro Oki1, Anas Younes2, Javier Knickerbocker2
1Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX 77030 USA yoki@mdanderson.org.
No abstract available in PubMed .
More Related Videos
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...